Wilson JM: Lessons learned from the gene therapy trial for ornithine transcarbamylase deficiency. Mol Genet Metab. 2009, 96 (4): 151-157.
Wilson RF: The death of Jesse Gelsinger: new evidence of the influence of money and prestige in human research. Am J Law Med. 2010, 36 (2–3): 295-325.
Wolf SM, Gupta R, Kohlhepp P: Gene therapy oversight: lessons for nanobiotechnology. J Law Med Ethics. 2009, 37 (01): 659-684.
Smith L, Byers JF: Gene transfer in the post-Gelsinger era. JONAS Healthc Law Ethics Regul. 2002, 4 (4): 104-110.
Yarborough M, Sharp RR: Public trust and research a decade later: what have we learned since Jesse Gelsinger’s death?. Mol Genet Metab. 2009, 97 (1): 4-5.
Bainbridge JWB, Smith AJ, Barker SS, Robbie S, Henderson R, Balaggan K, Viswanathan A, Holder GE, Stockman A, Bhattacharya SS, Thrasher AJ, Fitzke FW, Carter BJ, Rubin GS, Moore AT, Ali RR: Effect of gene therapy on visual function in Leber’s congenital amaurosis. N Engl J Med. 2008, 358 (21): 2231-2239.
Hauswirth WW, Aleman TS, Kaushal S, Cideciyan AV, Schwartz SB, Wang L, Conlon TJ, Boye SL, Flotte TR, Byrne BJ, Jacobson SG: Treatment of Leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Hum Gene Ther. 2008, 19 (10): 979-990.
Maguire AM, Simonelli F, Pierce EA, Pugh EN, Mingozzi F, Bennicelli J, Banfi S, Marshall KA, Testa F, Surace EM, Rossi S, Lyubarsky A, Arruda VR, Konkle B, Stone E, Sun J, Jacobs J, Dell’Osso L, Hertle R, Ma J, Redmond TM, Zhu X, Hauck B, Zelenaia O, Shindler KS, Maguire MG, Wright JF, Volpe NJ, McDonnell JW, Auricchio A: Safety and efficacy of gene transfer for Leber’s congenital amaurosis. N Engl J Med. 2008, 358 (21): 2240-2248.
Simonelli F, Maguire AM, Testa F, Pierce EA, Mingozzi F, Bennicelli JL, Rossi S, Marshall K, Banfi S, Surace EM, Sun J, Redmond TM, Zhu X, Shindler KS, Ying G, Ziviello C, Acerral C, Wright JF, McDonnell JW, High KA, Bennett J, Auricchio A: Gene therapy for Leber’s congenital amaurosis is safe and effective through 1.5 years after vector administration. Mol Ther. 2010, 18 (3): 643-650.
Smith AJ, Bainbridge JW, Ali RR: Prospects for retinal gene replacement therapy. Trends Genet. 2009, 25 (4): 156-165.
Kaplan J: Leber congenital amaurosis: from darkness to spotlight. Ophthalmic Genet. 2008, 29 (3): 92-98.
Heon E: My child has Leber congenital amaurosis: why is he/she not eligible for gene therapy trials?. J AAPOS. 2009, 13 (6): 533-534.
Caulfield T, Condit C: Science and the sources of hype. Public Health Genomics. 2012, 15 (3–4): 209-217.
Holtzman NA: Are genetic tests adequately regulated?. Science. 1999, 286 (5439): 409-
Gamson WA, Modigliani A: Media discourse and public opinion on nuclear power: a constructionist approach. Am J of Sociol. 1989, 95 (1): 1-37.
Nisbet M, Goidel R: Understanding citizen perceptions of science controversy: bridging the ethnographic survey research divide. Public Underst Sci. 2007, 16 (4): 421-440.
Nisbet MC, Brossard D, Kroepsch A: Framing science the stem cell controversy in an age of press/politics. IJPP. 2003, 8 (2): 36-70.
Caulfield T, Zarzeczny A, McCormick J, Bubela T, Critchley C, Einsiedel E, Galipeau J, Harmon S, Huynh M, Hyun I, Illes J, Isasi R, Joly Y, Laurie G, Lomax G, Longstaff H, Mcdonald M, Murdoch C, Ogbogu U, Owen-Smith J, Pattinson S, Premji S, von Tigerstrom B, Winickoff DE: The stem cell research environment: a patchwork of patchworks. Stem Cell Rev. 2009, 5 (2): 82-88.
Jensen E: Scientific sensationalism in American and British press coverage of therapeutic cloning. J Mass Commun Q. 2012, 89 (1): 40-54.
Bubela T, Hyde-Lay R, Lane S, Ogbogu U, Ouellette C, Nisbet MC, Borchelt R, Brunger F, Critchley C, Einsiedel E, Geller G, Gupta A, Hampel J, Hyde-Lay R, Jandciu EW, Jones SA, Kolopack P, Lane S, Lougheed T, Nerlich B, Ogbogu U, O’Riordan K, Ouellette C, Spear M, Strauss S, Thavaratnam T, Willemse L, Caulfield T: Science communication reconsidered. Nat Biotechnol. 2009, 27 (6): 514-518.
Myers EF, Parrott JS, Cummins DS, Splett P: Funding source and research report quality in nutrition practice-related research. PLoS One. 2011, 6 (12): e28437-
Cook DM, Boyd EA, Grossmann C, Bero LA: Journalists and conflicts of interest in science: beliefs and practices. Ethics Sci Environ Polit. 2009, 9: 33-40.
Petersen A: The ethics of expectations: biobanks and the promise of personalised medicine. Monash Bioeth Rev. 2009, 28 (1): 1-12.
Daugherty CK, Banik DM, Janish L, Ratain MJ: Quantitative analysis of ethical issues in phase I trials: a survey interview study of 144 advanced cancer patients. IRB. 2000, 22 (3): 6-14.
Pentz RD, Harvey RD, Owonikoko T, Khuri FR, White M, Farmer ZL, Liu Y, Lewis C, Dashevskaya O: Therapeutic misconception, misestimation, and optimism in participants enrolled in phase 1 trials. Cancer. 2012, 118 (18): 4571-4578.
Alliance for audited media.http://www.auditedmedia.com,
National Institutes of Health: ClinicalTrials.gov.http://www.clinicaltrials.gov/ct2/results/map?term=gene+therapy,
Bubela TM, Caulfield TA: Do the print media “hype” genetic research? A comparison of newspaper stories and peer-reviewed research papers. CMAJ. 2004, 170 (9): 1399-1407.
Bubela T, Boon H, Caulfield T: Herbal remedy clinical trials in the media: a comparison with the coverage of conventional pharmaceuticals. BMC Med. 2008, 6 (1): 35-
Condit CM: How geneticists can help reporters to get their story right. Nat Rev Genet. 2007, 8 (10): 815-820.
Holtzman NA, Bernhardt BA, Mountcastle-Shah E, Rodgers JE, Tambor E, Geller G: The quality of media reports on discoveries related to human genetic diseases. Community Genet. 2005, 8 (3): 133-144.
Nisbet MC: Framing Science: A New Paradigm in Public Engagement. Understanding Science: New Agendas in Science Communication. Edited by: Kahlor L, Stout P. 2009, New York: Taylor and Francis, 40-67.
Benjaminy S, MacDonald I, Bubela T: “Is a cure in my sight?”: Multi-stakeholder perspectives on phase I choroideremia gene transfer clinical trials. Genet Med. 2014, 16 (5): 379-385.
Neuendorf KA: The Content Analysis Guidebook. 2002, Thousand Oaks, California: Sage Publications
Campbell J: Science Gives Blind Dogs Sight: ‘First Fruit of Genetic revolution’ Raises Hope for Fighting Other Genetic Diseases. 2001, Ottawa: The Ottawa Citizen
Sample I: Gene Therapy Aimed at Restoring Sight for 30,000 People. 2007, London: The Guardian
Mick H: Gene Therapy Shines Light on Blindness. 2008, Toronto: The Globe and Mail
Willey J: Blind Will ‘see’ Within a few Days of Gene Therapy. 2008, London: The Daily Express
Ransohoff DF, Ransohoff RM: Sensationalism in the media: when scientists and journalists may be complicit collaborators. Eff Clin Pract. 2001, 4 (4): 185-188.
Hedgecoe A: The Politics of Personalised Medicine: Pharmacogenetics in the Clinic. 2004, Cambridge: Cambridge University Press
Brechman JM, Lee CJ, Cappella JN: Distorting genetic research about cancer: from bench science to press release to published news. J Commun. 2011, 61 (3): 496-513.
Ogbogu U, Du L, Rachul C, Bélanger L, Caulfield T: Chinese newspaper coverage of (unproven) stem cell therapies and their providers. Stem Cell Rev. 2013, 9 (2): 1-8.
Horst M: Public expectations of gene therapy scientific futures and their performative effects on scientific citizenship. Sci Technol Hum Values. 2007, 32 (2): 150-171.
Critchley CR: Public opinion and trust in scientists: the role of the research context, and the perceived motivation of stem cell researchers. Public Underst Sci. 2008, 17 (3): 309-327.
Kimmelman J: Gene Transfer and the Ethics of First-in-Human Research: Lost in Translation. 2010, Cambridge: Cambridge University Press
Tsfati Y, Cohen J, Gunther AC: The influence of presumed media influence on news about science and scientists. Sci Commun. 2011, 33 (2): 143-166.
Henderson L, Kitzinger J: The human drama of genetics: ‘hard’ and ‘soft’ media representations of inherited breast cancer. Sociol Health Illn. 1999, 21 (5): 560-578.
McKeever BW: News framing of autism understanding media advocacy and the combating Autism Act. Sci Commun. 2013, 35 (2): 213-240.
Kitzinger J, Williams C: Forecasting science futures: legitimising hope and calming fears in the embryo stem cell debate. Soc Sci Med. 2005, 61 (3): 731-740.
Petersen A: Biofantasies: genetics and medicine in the print news media. Soc Sci Med. 2001, 52 (8): 1255-1268.
Jensen E: Mediating subpolitics in US and UK science news. Public Underst Sci. 2012, 21 (1): 68-83.
Nisbet MC, Scheufele DA: What’s next for science communication? Promising directions and lingering distractions. Am J Bot. 2009, 96 (10): 1767-1778.
Racine E, Waldman S, Rosenberg J, Illes J: Contemporary neuroscience in the media. Soc Sci Med. 2010, 71 (4): 725-733.
Critchley CR, Nicol D: Understanding the impact of commercialization on public support for scientific research: is it about the funding source or the organization conducting the research?. Public Underst Sci. 2011, 20 (3): 347-366.
Vicsek L: Costs and benefits of stem cell research and treatment: media presentation and audience understanding in Hungary. Sci Commun. 2011, 33 (3): 309-340.
Caulfield T, McGuire AL: Direct-to-consumer genetic testing: perceptions, problems, and policy responses. Annu Rev Med. 2012, 63: 23-33.
Condit C: What is ‘public opinion’ about genetics?. Nat Rev Genet. 2001, 2 (10): 811-815.
Wilde A, Bonfiglioli C, Meiser B, Mitchell PB, Schofield PR: Portrayal of psychiatric genetics in Australian print news media, 1996–2009. Med J Aust. 2011, 195 (7): 401-404.
Robillard JM, Whiteley L, Johnson TW, Lim J, Wasserman WW, Illes J: Utilizing social media to study information-seeking and ethical issues in gene therapy. J Med Internet Res. 2013, 15 (3): e44-
Acland GM, Aguirre GD, Ray J, Zhang Q, Aleman TS, Cideciyan AV, Pearce-Kelling SE, Anand V, Zeng Y, Maguire AM, Jacobson SG, Hauswirth WW, Bennett J: Gene therapy restores vision in a canine model of childhood blindness. Nat Genet. 2001, 28 (1): 92-95.
Appelbaum PS, Roth LH, Lidz C: The therapeutic misconception: informed consent in psychiatric research. Int J Law Psychiatry. 1982, 5 (3–4): 3-4.
Horng S, Grady C: Misunderstanding in clinical research: distinguishing therapeutic misconception, therapeutic misestimation, and therapeutic optimism. IRB. 2003, 25 (1): 11-16.
Pentz RD, Flamm AL, Sugarman J, Cohen MZ, Ayers GD, Herbst RS, Abbruzzese JL: Study of the media’s potential influence on prospective research participants’ understanding of and motivations for participation in a high-profile phase I trial. J Clin Oncol. 2002, 20 (18): 3785-3791.
Jacobson SG, Aleman TS, Cideciyan AV, Sumaroka A, Schwartz SB, Windsor EAM, Traboulsi EI, Heon E, Pittler SJ, Milam AH, Maguire AM, Placzewski K, Stone EM, Bennett J: Identifying photoreceptors in blind eyes caused by RPE65 mutations: prerequisite for human gene therapy success. Proc Natl Acad Sci U S A. 2005, 102 (17): 6177-6182.
Cideciyan AV, Jacobson SG, Beltran WA, Sumaroka A, Swider M, Iwabe S, Roman AJ, Olivares MB, Schwartz SB, Komáromy AM, Hauswirth WW, Aguirre GD: Human retinal gene therapy for Leber congenital amaurosis shows advancing retinal degeneration despite enduring visual improvement. Proc Natl Acad Sci U S A. 2013, 110 (6): E517-E525.
Kimmelman J: Ethics of cancer gene transfer clinical research. Methods Mol Biol. 2009, 542: 423-445.
Reimer J, Borgelt E, Illes J: In pursuit of “informed hope” in the stem cell discourse. Am J Bioeth. 2010, 10 (5): 31-32.